Phosphodiesterase 4-targeted Treatments for Autoimmune Diseases

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2013 Apr 6

PMID 23557064

Citations 48

Authors

Neal Kumar

Ari M Goldminz

Noori Kim

Alice B Gottlieb

Affiliations

Soon will be listed here.

Abstract

Advancements in phosphodiesterase (PDE)-targeted therapies have shown promise in recent years for treating patients with a variety of autoimmune diseases. This review summarizes the development of PDE4 inhibitors and the associated literature with a focus on treatments for autoimmune diseases. After the initial investigations of the prototypic PDE inhibitor, rolipram, more selective inhibitors targeting the PDE4 isozyme have been developed. With phase II and phase III clinical trials currently underway to evaluate the safety and efficacy of the latest generation of PDE4 inhibitors, namely apremilast, a new class of treatments may be around the corner for patients suffering from chronic, autoimmune diseases.

Citing Articles

Safety, pharmacokinetics, and pharmacodynamics of ART-648, a PDE4 inhibitor in healthy subjects: A randomized, placebo-controlled phase I study.

Tanaka A, Nagabukuro H, Kuniyeda K, Ando H, Higashi T, Wakuda H Clin Transl Sci. 2024; 17(10):e70024.

PMID: 39356093 PMC: 11445709. DOI: 10.1111/cts.70024.

Design, synthesis, molecular docking, and molecular dynamic studies of novel quinazoline derivatives as phosphodiesterase 7 inhibitors.

El-Malah A, Gineinah M, Khayat M, Aljahdali A, Safar M, Almazmumi H Front Pharmacol. 2024; 15:1389076.

PMID: 38711988 PMC: 11070508. DOI: 10.3389/fphar.2024.1389076.

Endothelial phosphodiesterase 4B inactivation ameliorates endothelial-to-mesenchymal transition and pulmonary hypertension.

Xing Y, Hou Y, Fan T, Gao R, Feng X, Li B Acta Pharm Sin B. 2024; 14(4):1726-1741.

PMID: 38572107 PMC: 10985131. DOI: 10.1016/j.apsb.2024.01.012.

PDE4 Phosphodiesterases in Cardiovascular Diseases: Key Pathophysiological Players and Potential Therapeutic Targets.

Puertas-Umbert L, Alonso J, Hove-Madsen L, Martinez-Gonzalez J, Rodriguez C Int J Mol Sci. 2023; 24(23).

PMID: 38069339 PMC: 10707411. DOI: 10.3390/ijms242317017.

Ginger intake suppresses neutrophil extracellular trap formation in autoimmune mice and healthy humans.

Ali R, Minarchick V, Zahavi M, Rysenga C, Sturm K, Hoy C JCI Insight. 2023; 8(18).

PMID: 37737262 PMC: 10561719. DOI: 10.1172/jci.insight.172011.

References

Giembycz M . Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?. Drugs. 2000; 59(2):193-212. DOI: 10.2165/00003495-200059020-00004. View

Christensen S, Guider A, Forster C, Gleason J, Bender P, Karpinski J . 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J Med Chem. 1998; 41(6):821-35. DOI: 10.1021/jm970090r. View

van der Heijde D, Sieper J, Maksymowych W, Dougados M, Burgos-Vargas R, Landewe R . 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011; 70(6):905-8. DOI: 10.1136/ard.2011.151563. View

Monneaux F, Muller S . Molecular therapies for systemic lupus erythematosus: clinical trials and future prospects. Arthritis Res Ther. 2009; 11(3):234. PMC: 2714128. DOI: 10.1186/ar2711. View

Podolsky D . Inflammatory bowel disease. N Engl J Med. 2002; 347(6):417-29. DOI: 10.1056/NEJMra020831. View

Baraliakos X, Hermann K, Braun J . Imaging in axial spondyloarthritis: diagnostic problems and pitfalls. Rheum Dis Clin North Am. 2012; 38(3):513-22. DOI: 10.1016/j.rdc.2012.08.011. View

Abdi A, Sadraie H, Dargahi L, Khalaj L, Ahmadiani A . Apoptosis inhibition can be threatening in Aβ-induced neuroinflammation, through promoting cell proliferation. Neurochem Res. 2010; 36(1):39-48. DOI: 10.1007/s11064-010-0259-3. View

Butler J, Chan S, Stevens S, Hanifin J . Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J Allergy Clin Immunol. 1983; 71(5):490-7. DOI: 10.1016/0091-6749(83)90467-0. View

Goncalves R, Lugnier C, Keravis T, Lopes M, Fantini F, Schmitt M . The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue. Eur J Pharmacol. 2009; 620(1-3):78-83. DOI: 10.1016/j.ejphar.2009.08.008. View

10.

Henney C, Lichtenstein L . The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol. 1971; 107(2):610-2. View

11.

Dyke H, Montana J . Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs. 2002; 11(1):1-13. DOI: 10.1517/13543784.11.1.1. View

12.

Hartung H, Kieseier B . The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol. 2000; 107(2):140-7. DOI: 10.1016/s0165-5728(00)00225-3. View

13.

Feldmann M, Maini R . Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003; 9(10):1245-50. DOI: 10.1038/nm939. View

14.

Gordon J, Prothero J, Thornton C, Pickard K, di Sabatino A, Goggin P . CC-10004 but not thalidomide or lenalidomide inhibits lamina propria mononuclear cell TNF-α and MMP-3 production in patients with inflammatory bowel disease. J Crohns Colitis. 2010; 3(3):175-82. DOI: 10.1016/j.crohns.2009.03.001. View

15.

Peluso M . Flavonoids attenuate cardiovascular disease, inhibit phosphodiesterase, and modulate lipid homeostasis in adipose tissue and liver. Exp Biol Med (Maywood). 2006; 231(8):1287-99. DOI: 10.1177/153537020623100802. View

16.

Sommer N, Martin R, McFarland H, Quigley L, Cannella B, Raine C . Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J Neuroimmunol. 1997; 79(1):54-61. DOI: 10.1016/s0165-5728(97)00111-2. View

17.

ODonnell J, Zhang H . Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci. 2004; 25(3):158-63. DOI: 10.1016/j.tips.2004.01.003. View

18.

Manning C, Burman M, Christensen S, Cieslinski L, Essayan D, Grous M . Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol. 1999; 128(7):1393-8. PMC: 1571768. DOI: 10.1038/sj.bjp.0702911. View

19.

Nazarian R, Weinberg J . AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009; 10(11):1236-42. View

20.

Khoruts A, Miller S, Jenkins M . Neuroantigen-specific Th2 cells are inefficient suppressors of experimental autoimmune encephalomyelitis induced by effector Th1 cells. J Immunol. 1995; 155(10):5011-7. View